Stock · ABBV · Healthcare
United States · Large Cap · listed since 2013 · Revenue 12 mo. $64.4B
Price as of 11/06/2026
Summary
51.5 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €16B (2025), it supports €177.6B. The remaining €294B of the market value assume it grows 13.6% a year for 10 years and not at all afterwards.
Required FCF growth per year
13.6%
no growth afterwards
Price to operating cash flow 26.4×, above its usual range.
Middle half of 20 quarters: 11.3× to 18.6×, median 13.4×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
AI summary of the 2025 annual report
A language model selected and condensed statements from the report. Each statement carries a verbatim quote. The selection is not complete and shows the state of the report. It gives no rating and does not feed into the score.
Form 10-K, fiscal year ended 12/31/2025, filed 02/20/2026. Open the report at the SEC
Skyrizi (risankizumab) is a drug that blocks interleukin-23 (IL-23).
Skyrizi (risankizumab) is an interleukin-23 (IL-23) inhibitorUbrelvy is a drug that blocks calcitonin gene-related peptide receptors, used for acute treatment of migraine with or without aura in adults.
Ubrelvy (ubrogepant) is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.Juvederm Collection is a range of dermal fillers made from hyaluronic acid, used to add volume or treat volume loss in areas such as the cheeks, chin, lips and lower face.
Juvederm Collection is a portfolio of hyaluronic acid-based dermal fillers with a variety of approved indications in the U.S. and in other major markets around the world to augment or treat volume loss in the temples, undereye, cheeks, chin, lips and lower face.AbbVie generally sells its products worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.
AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailersCertain products, including aesthetic products and devices, are also sold directly to doctors and other licensed health care providers.
Certain products (including aesthetic products and devices) are also sold directly to physicians and other licensed healthcare providers.Managed care providers, such as health maintenance organizations and pharmacy benefit managers, hospitals and government agencies are also important customers.
Managed care providers (for example, health maintenance organizations and pharmacy benefit managers), hospitals and state and federal government agenciesOutside the United States, AbbVie mainly sells products to wholesalers or through distributors.
Outside the United States, AbbVie sells products primarily to wholesalers or through distributorsAbbVie's immunology products compete with IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, biosimilars and other products intended to treat a number of disease states.
AbbVie's immunology products compete with IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, biosimilars and other competitive products intended to treat a number of disease statesPrice is also a factor in competition.
Price is also a competitive factor.The search for technological innovation in pharmaceutical products is a significant part of competition.
The search for technological innovations in pharmaceutical products is a significant aspect of competition.Skyrizi and Rinvoq each made up more than 10% of total net revenues, and together they accounted for approximately 42% of total net revenues in 2025.
Skyrizi and Rinvoq each represented greater than 10% of AbbVie's total net revenues and, in aggregate, these products accounted for approximately 42% of total net revenues in 2025.Humira faces direct competition from biosimilars worldwide.
Humira faces direct biosimilar competition globallyThe US patents on the substances risankizumab and upadacitinib, which protect the chemical itself, are expected to expire in 2033.
The United States composition of matter patents covering risankizumab and upadacitinib are expected to expire in 2033.In August 2023, the US health department, through CMS, selected Imbruvica as one of 10 medicines subject to government-set prices.
In August 2023, the U.S. Department of Health and Human Services (HHS), through CMS, selected Imbruvica as one of 10 medicines subject to government-set pricesAbbVie judges that the cost of product liability insurance outweighs the likely benefits of the coverage available, so its product liability losses are self-insured.
AbbVie evaluates its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, AbbVie's product liability losses are self-insured.Since the last quarter
Q1 → Q2 2026
4 more unchanged: Revenue, 12 mo., Gross margin, Net debt, Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 68.01% | 11.52% | Rank 97 |
| Return on capital (Greenblatt) | 315.65% | 32.55% | Rank 99 |
| EBIT margin | 32.85% | 18.31% | Rank 89 |
| FCF margin | 29.13% | 14.12% | Rank 91 |
| Gross margin | 70.24% | 60.99% | Rank 65 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 8.57% | 8.04% | Rank 53 |
| Earnings growth, 3 years per year | −29.00% | 5.44% | Rank 6 |
| Earnings growth, 5 years per year | −2.90% | 7.00% | Rank 25 |
| Sustainable growth (ROE × retained earnings) | 1.98% | 3.66% | Rank 23 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 0.82% | 2.90% | Rank 13 |
| FCF yield | 3.39% | 3.63% | Rank 45 |
| EV/saleslower is better | 9.64 | 4.03 | Rank 16 |
| EV/EBITlower is better | 29.34 | 21.73 | Rank 30 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 23.39% | 8.66% | Rank 72 |
| Share price, 6 months | 45.02% | 24.27% | Rank 83 |
| Share price, 3 months | 23.53% | 15.42% | Rank 76 |
| Distance from 52-week high | −1.21% | −7.35% | Rank 81 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −6.06% | 0.30% | Rank 90 |
| Change in share countlower is better | 0.06% | 0.00% | Rank 34 |
| Dividend streak in years | 12 | 10 | Rank 65 |
| Price reaction to results, market-adjusted | 3.01% | 0.05% | Rank 74 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | −2.41% | 48.40% | Rank 3 |
| Net debt/EBITDAlower is better | 3.62 | 1.11 | Rank 10 |
| Debt to equitylower is better | 2.65 | 0.48 | Rank 3 |
| Volatility, 1 yearlower is better | 25.92% | 31.42% | Rank 84 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 25.6 | 36.4% | 6.6 | 1.63B | 31.7 |
| 2017 | 28.2 | 33.8% | 9.4 | 1.60B | 28.1 |
| 2018 | 32.8 | 19.5% | 12.8 | 1.55B | 33.0 |
| 2019 | 33.3 | 39.0% | 12.8 | 1.48B | 27.2 |
| 2020 | 45.8 | 24.8% | 16.8 | 1.67B | 78.6 |
| 2021 | 56.2 | 31.9% | 22.0 | 1.78B | 67.8 |
| 2022 | 58.1 | 31.2% | 24.2 | 1.78B | 55.0 |
| 2023 | 54.3 | 23.5% | 22.1 | 1.77B | 47.3 |
| 2024 | 56.3 | 16.2% | 17.8 | 1.77B | 62.3 |
| 2025 | 61.2 | 32.9% | 17.8 | 1.77B | 63.8 |
4 of 7 StockScorer Score rules met · How the score is built
AbbVie Inc mainly meets criteria in the Profitability category. Result from 18 strategies checked.
AbbVie Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
4 of 7 rules met
6 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for AbbVie Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 122.3 | 30.0 |
| P/B ratio | 16.5 | 4.8 |
| Return on equity (ROE) | 68.0% | 11.5% |
| Equity ratio | −2.4% | 48.4% |
| Debt-to-equity (D/E) | 2.65 | 0.48 |
| Dividend yield | 2.4% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| ABBV | AbbVie Incthis page | |
| JNJ | Johnson & Johnson | High6.4 |
| MRK | Merck & Company Inc | Medium5.5 |
| AMGN | Amgen Inc | Medium5.5 |
| GILD | Gilead Sciences Inc | locked |
| PFE | Pfizer Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.